Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com
Latest Financials

Filings:

CategoryDateSearch FilingsInstitutional HoldersbetaEarnings TranscriptsbetaGlobal Search

SEC Edgar

21st Century Oncology Holdings, Inc.

SIC 8011 · Services-Offices & Clinics Of Doctors Of Medicine
NotesSupport
aboutterms

21st Century Oncology Holdings, Inc.

CIK:0001503518|SEC Filings
v3.5.0.2
Consolidated Statements Of Operations And Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenues:        
Net patient service revenue $ 226,505 $ 243,768 $ 715,974 $ 755,877
Management fees 14,240 14,180 43,514 45,261
Other revenue 4,934 4,309 14,872 14,965
Total revenues 245,679 262,257 774,360 816,103
Expenses:        
Salaries and benefits 136,859 142,640 414,610 436,996
Medical supplies 22,211 22,498 74,215 73,563
Facility rent expenses 17,440 16,983 52,304 50,821
Other operating expenses 16,007 15,951 47,678 46,994
General and administrative expenses 35,344 68,306 101,070 141,341
Depreciation and amortization 21,319 22,439 63,412 66,775
Provision for doubtful accounts 8,610 5,617 17,270 13,683
Interest expense, net 27,151 23,771 77,353 73,836
Other gains and losses 481 (5,696) (12,699) (7,363)
Impairment loss 770   2,595  
Early extinguishment of debt       37,390
Fair value measurements 34,976 1,799 22,187 8,404
(Gain) loss on foreign currency transactions (5) 333 300 537
Total expenses 321,163 314,641 860,295 942,977
Loss before income taxes and equity interest in net income of joint ventures (75,484) (52,384) (85,935) (126,874)
Income tax expense 3,166 2,851 7,967 7,198
Net loss before equity interest in net income of joint ventures (78,650) (55,235) (93,902) (134,072)
Equity interest in net income of joint ventures, net of tax 150 (10) 957 202
Net loss (78,500) (55,245) (92,945) (133,870)
Net income attributable to noncontrolling interests - redeemable and non-redeemable (1,422) (2,530) (4,534) (6,610)
Net loss attributable to 21st Century Oncology Holdings, Inc. shareholder (79,922) (57,775) (97,479) (140,480)
Other comprehensive loss, net of tax:        
Unrealized loss on foreign currency translation (1,150) (2,415) (5,146) (6,414)
Other comprehensive loss (1,150) (2,415) (5,146) (6,414)
Comprehensive loss (79,650) (57,660) (98,091) (140,284)
Comprehensive income attributable to noncontrolling interests-redeemable and non-redeemable: (1,429) (2,067) (3,780) (5,599)
Comprehensive loss attributable to 21st Century Oncology Holdings, Inc. shareholder $ (81,079) $ (59,727) $ (101,871) $ (145,883)